Source: Clearside Biomedical, Inc. its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial par ...

Clearside Biomedical, Inc. (NASDAQ:CLSD) Suprachoroidal Space Drug Delivery Call July 24, 2024 8:00 AM ET Company Participants Jenny Kobin - Investor Relations George Lasezkay - President and Chief Executive Officer Glenn Yiu - Scientific Advisory Board Victor Chong - Chief Medical Officer David Brown - Director of Research, Retina Consultants Houston Conference Call Participants Annabel Samimy - Stifel Andreas Argyrides - Oppenheimer & Co. Serge Belanger - Needham & Company Yi Chen - H.C. Wainwright Operat ...

Core Insights - Clearside Biomedical is focused on the potential of suprachoroidal drug delivery, positioning itself as a leader in this innovative space with a proprietary SCS Microinjector that has been validated through numerous clinical injections [7][10][37] - The company has developed the first FDA-approved product for suprachoroidal administration, XIPERE, which is currently being commercialized in the U.S. and is seeking approval in Canada and Australia [12][37] - The pipeline includes CLS-AX, a tyrosine kinase inhibitor for wet AMD, which is completing Phase IIb trials, with data expected in late Q3 2024 [8][11][56] Company Overview - Clearside Biomedical has established multiple strategic collaborations to enhance its capabilities in the suprachoroidal space, including partnerships with Aura, REGENXBIO, AbbVie, and BioCryst [13][14] - The company has a comprehensive intellectual property portfolio surrounding its microinjector platform, which supports various drug categories for retinal diseases [7][10] Product Development - The SCS Microinjector has been used in over 10,000 injections without reported cases of endophthalmitis, indicating a favorable safety profile compared to traditional intravitreal injections [40] - XIPERE has shown promising real-world efficacy, with approximately 86.5% of patients not requiring rescue therapy within six months, comparable to clinical trial results [30][37] Market Potential - The market for geographic atrophy is considered larger than that for wet AMD, with ongoing research into improving treatment efficacy and duration [58] - The company aims to leverage its expertise in suprachoroidal delivery to develop therapies targeting geographic atrophy, which is increasingly recognized as a choroidal disease [62][66] Future Outlook - Clearside Biomedical plans to initiate a Phase III study for CLS-AX, which is expected to provide data that could facilitate its approval and integration into clinical practice [55][56] - The company is exploring the potential of gene therapy applications through its suprachoroidal delivery system, which may offer advantages over traditional methods [66][68]

The event will include presentations by the following retinal experts concluding with a live question-andanswer session with the KOLs and Clearside senior management: Any statements contained in this press release that do not describe historical facts may constitute forwardlooking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan", "potential", "will", and similar expressions, and ...

ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Glenn C. Yiu, M.D., Ph.D., Professor of Ophthalmology at the University of California, Davis, to its Scientific Advisory Board (SAB), which is comprised of industry-leading retinal physicians who provide medical and scientific expertise and input on ...

ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Glenn C. Yiu, M.D., Ph.D., Professor of Ophthalmology at the University of California, Davis, to its Scientific Advisory Board (SAB), which is comprised of industry-leading retinal physicians who provide medical and scientific expertise and input on ...

- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery - - Target Profile for CLS-AX in Wet AMD Landscape and Potential Opportunities for Clearside Pipeline Expansion - ALPHARETTA, Ga., June 27, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), anno ...

ALPHARETTA, Ga., June 27, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced plans to host a virtual key opinion leader (KOL) event on Wednesday, July 24, 2024 from 8:00 - 9:15 am ET. The live and archived webcast will be accessible on the Clearside website under the Investors section: Events and Presentations. - Retina Specialists to Provide Insigh ...

- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - "Clearside is leading the way in suprachoroidal delivery, including having the only FDA approved product for suprachoroidal use and a second program with an expected near-term clinical data readout for CLS-AX in the large wet AMD market," said Victor Chong, M.D., MBA, Chief Medical Officer of Clearside. "We believe that suprachoroidal delivery combined with the differentiated mechanism of action and high potency of axi ...

- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - Title: Suprachoroidal Drug Delivery in the Real World Presented by: Glenn Yiu , M.D., PhD Summary: Additional Presentations Delivered by Clearside Commercial and Development Partners ALPHARETTA, Ga., June 12, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced t ...